Oncimmune reports H1 pretax loss as costs soar

13 February 2018, 07:43

Source - SMW

Oncimmune reported a pretax loss to £2.8m for the six months to 30 November 2017, from a year-earlier loss of £2.5m while revenue for the period was just £77,000, down from £114,000.
The wider pre-tax loss came as cost of sales soared more than 400% to £444,000 from just £109,000 a year ago amid an increase in the cost of kit samples provided to distributors and a general increase in the operating cost of the US central laboratory.
Geoffrey Hamilton-Fairley, CEO of Oncimmune, said: 'Oncimmune continues to make excellent progress in delivering on the potential of our platform to detect up to four years earlier than other methods based on a simple, robust, blood test - a liquid biopsy.'
'We have recently entered an exclusive distribution and product development agreement in China which includes a £10m equity investment and £15.7m in minimum royalties. We have now secured agreements for 12 countries with minimum sales commitments of £25.6m.'
'We have also entered a preliminary distribution partnership with a major US pulmonology salesforce which is progressing well and, if successful, should lead to a significant distribution agreement focused on the risk detection of indeterminate pulmonary nodules - a large and growing market.'

Market Overview

UK 350 Risers and Fallers

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies from this website. If you would like to change your preferences you may do so by following the instructions here.